ProMIS Neurosciences (PMN) Non-Current Debt (2021)
ProMIS Neurosciences' (PMN) quarterly Non-Current Debt came in at $3.9 million in Q4 2021.
ProMIS Neurosciences (PMN) Non-Current Debt (2021) Analysis & Trends
ProMIS Neurosciences (PMN) has 1 years of Non-Current Debt data on file, last reported at $3.9 million in Q4 2021.
- Quarterly Non-Current Debt changed N/A year-over-year to $3.9 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $3.9 million (changed N/A YoY) and the FY2021 annual result came in at $3.9 million, changed N/A from the prior year.
- Non-Current Debt was little changed at $3.9 million in Q4 2021.
- In the past five years, Non-Current Debt ranged from a high of $3.9 million in Q4 2021 to a low of $3.9 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 8.96 Bn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 3.91 Mn |